Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15:12 | Notable healthcare headlines for the week: Novo Nordisk, Amgen and UnitedHealth in focus | 32 | Seeking Alpha | ||
AMGEN INC CDR Aktie jetzt für 0€ handeln | |||||
Fr | Amgen-Aktie mit Kursverlusten (237,1233 €) | 419 | ARIVA.de | An der US-amerikanischen Börse notiert die Aktie von Amgen derzeit etwas leichter. Der jüngste Kurs betrug 277,19 US-Dollar. An der Börse liegt die Aktie von Amgen zur Stunde im Minus. Das Wertpapier... ► Artikel lesen | |
Fr | Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed? | 8 | Zacks | ||
Di | Where Amgen Stands With Analysts | 18 | Benzinga.com | ||
Di | New Amgen obesity drug data disappoint Wall Street | 18 | BioPharma Dive | ||
Di | Amgen stock rating reiterated at Buy by TD Cowen on Maritide potential | 10 | Investing.com | ||
Di | Amgen rolls out phase 3 dosing plan for lead obesity candidate after midstage trial sees high discontinuation, vomiting rates | 6 | FierceBiotech | ||
Di | BMO Capital reiterates Amgen stock rating with $346 price target | 15 | Investing.com | ||
Di | BMO Capital bekräftigt Amgen-Bewertung mit Kursziel von 346 US-Dollar | 6 | Investing.com Deutsch | ||
Di | Truist reiterates Amgen stock hold rating amid MariTide obesity data | 11 | Investing.com | ||
Di | What's Happening With Amgen Stock? | 22 | Forbes | ||
Di | Amgen stock maintains Overweight rating at Piper Sandler despite GI data | 5 | Investing.com | ||
Di | Amgen-Aktie behält Overweight-Rating bei Piper Sandler trotz GI-Daten | 10 | Investing.com Deutsch | ||
Mo | Amgen falls despite positive weight loss trial results | 48 | Seeking Alpha | ||
Mo | Amgen stock falls after obesity drug MariTide shows 20% weight loss | 29 | Investing.com | ||
Mo | Amgen-Aktie fällt nach 20% Gewichtsverlust durch Adipositas-Medikament MariTide | 117 | Investing.com Deutsch | ||
Mo | Amgens Adipositas-Medikament zeigt bis zu 20% Gewichtsverlust in Phase-2-Studie | 47 | Investing.com Deutsch | ||
Mo | Amgen Expands Development Plans For Highly Anticipated Obesity Drug | 11 | Investor's Business Daily | ||
Mo | Amgen's obesity drug shows up to 20% weight loss in phase 2 trial | 12 | Investing.com | ||
Mo | Results From Amgen's Phase 2 Obesity Study Of Monthly Maritide Presented At The American Diabetes Association 85th Scientific Sessions | 326 | PR Newswire | MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -6,35 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |